Interleukin signaling mitigates the inhibitory effects of combined Src/BCR-ABL1 blockade on T-cell activity in Philadelphia chromosome-positive acute lymphoblastic leukemia
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), driven by the BCR-ABL1 fusion gene, remains a high-risk malignancy despite therapeutic advances. Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have significantly improved outcomes, but resistance and relapse persist, ne...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Ferrata Storti Foundation
2026-02-01
|
| Seri Bilgileri: | Haematologica |
| Online Erişim: | https://haematologica.org/article/view/13140 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|